Zanamivir
From Proteopedia
(Difference between revisions)
| Line 2: | Line 2: | ||
{| class="wikitable" border="1" width="52%" style="text-align:center" | {| class="wikitable" border="1" width="52%" style="text-align:center" | ||
|- | |- | ||
| - | ! colspan="12" align="center"| Neuraminidase Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir (RELENZA™) 10mg Administered Twice Daily for 5 Days by Rotacap/Rotahaler Compared to ROTADISK™/DISKHALER™ in Healthy Subjects, Study No: NAI113625, 2009</ref> | + | ! colspan="12" align="center"| Neuraminidase Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir (RELENZA™) 10mg Administered Twice Daily for 5 Days by Rotacap/Rotahaler Compared to ROTADISK™/DISKHALER™ in Healthy Subjects, Study No: NAI113625, 2009</ref><ref>DOI: 10.1007/s00228-003-0639-6</ref> |
|- | |- | ||
! Parameter | ! Parameter | ||
| Line 10: | Line 10: | ||
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr) | ! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr) | ||
! 1.25 | ! 1.25 | ||
| - | ! | + | ! 1.5 |
|- | |- | ||
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ||
! 31.6 | ! 31.6 | ||
| - | ! | + | ! 57 |
|- | |- | ||
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%) | ! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%) | ||
! 2 | ! 2 | ||
| - | ! | + | ! 75 |
|- | |- | ||
! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%) | ! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%) | ||
| Line 26: | Line 26: | ||
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ||
! 3 | ! 3 | ||
| - | ! | + | ! 3.2 |
|- | |- | ||
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
! 185 | ! 185 | ||
| - | ! | + | ! 204 |
|- | |- | ||
! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h) | ! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h) | ||
| Line 38: | Line 38: | ||
! Dosage (mg) | ! Dosage (mg) | ||
! 10 | ! 10 | ||
| - | ! | + | ! 300 |
|- | |- | ||
! Metabolism | ! Metabolism | ||
Revision as of 15:05, 8 December 2010
Pharmacokinetics
| Neuraminidase Inhibitor Pharmacokinetics[1][2] | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Ritonavir | Oseltamivir | |||||||||
| Tmax (hr) | 1.25 | 1.5 | |||||||||
| Cmax (ng/ml) | 31.6 | 57 | |||||||||
| Bioavailability (%) | 2 | 75 | |||||||||
| Protein Binding (%) | 10 | Oseltamivir | |||||||||
| T1/2 (hr) | 3 | 3.2 | |||||||||
| AUC (ng/ml/hr) | 185 | 204 | |||||||||
| Clearance (L/h) | 54.1 | Oseltamivir | |||||||||
| Dosage (mg) | 10 | 300 | |||||||||
| Metabolism | None | Oseltamivir | |||||||||
